The Latest Breaking News from Lilly

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.

Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

Costco stock is in a buy zone ahead of the earnings report Thursday. Mutual funds like this stock and a few others.

The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?

Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.